RT Journal Article
T1 Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry).
A1 Lopez-Tarruella, Sara
A1 Escudero, M J
A1 Pollan, Marina
A1 Martin, Miguel
A1 Jara, Carlos
A1 Bermejo, Begoña
A1 Guerrero-Zotano, Angel
A1 Garcia-Saenz, Jose
A1 Santaballa, Ana
A1 Alba, Emilio
A1 Andres, Raquel
A1 Martinez, Purificacion
A1 Calvo, Lourdes
A1 Fernandez, Antonio
A1 Batista, Norberto
A1 Llombart-Cussac, Antonio
A1 Anton, Antonio
A1 Lahuerta, Ainhara
A1 de la Haba, Juan
A1 Lopez-Vega, Jose Manuel
A1 Carrasco, E
K1 Cancer epidemiology
K1 Breast cancer
AB The debate about surgical resection of primary tumor (PT) in de novo metastatic breast cancer (MBC) patients persists. We explored this approach's outcomes in patients included in a retrospective registry, named El Álamo, of breast cancer patients diagnosed in Spain (1990-2001). In this analysis we only included de novo MBC patients, 1415 of whom met the study's criteria. Descriptive, Kaplan-Meier and Cox regression analyses were carried out. Median age was 63.1 years, 49.2% of patients had single-organ metastasis (skin/soft tissue [16.3%], bone [33.8%], or viscera [48.3%]). PT surgery (S) was performed in 44.5% of the cases. S-group patients were younger, had smaller tumors, higher prevalence of bone and oligometastatic disease, and lower prevalence of visceral involvement. With a median follow-up of 23.3 months, overall survival (OS) was 39.6 versus 22.4 months (HR = 0.59, p 
PB Nature Publishing Group
YR 2019
FD 2019-12-02
LK http://hdl.handle.net/10668/14894
UL http://hdl.handle.net/10668/14894
LA en
NO Lopez-Tarruella S, Escudero MJ, Pollan M, Martín M, Jara C, Bermejo B, et al. Survival impact of primary tumor resection in de novo metastatic breast cancer patients (GEICAM/El Alamo Registry). Sci Rep. 2019 Dec 27;9(1):20081.
DS RISalud
RD Apr 7, 2025